Date:12 th June 2022
Your Name:Han Ding
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal sten
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

5				
3	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	None	
6	Payment for expert testimony	None	None	
7	Support for attending meetings and/or travel	None	None	
8	Patents planned, issued or pending	None	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	None	
11	Stock or stock options	None	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	None	
13	Other financial or non- financial interests	None	None	

Т	ere is no conflict of interest	

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Ang Li
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal ster
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

5				
3	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	None	
6	Payment for expert testimony	None	None	
7	Support for attending meetings and/or travel	None	None	
8	Patents planned, issued or pending	None	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	None	
11	Stock or stock options	None	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	None	
13	Other financial or non- financial interests	None	None	

Т	ere is no conflict of interest	

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Chao Sun
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal sten
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

5				
3	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	None	
6	Payment for expert testimony	None	None	
7	Support for attending meetings and/or travel	None	None	
8	Patents planned, issued or pending	None	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	None	
11	Stock or stock options	None	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	None	
13	Other financial or non- financial interests	None	None	

Т	ere is no conflict of interest	

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Jianping Zhang
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal sten
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

5				
3	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	None	
6	Payment for expert testimony	None	None	
7	Support for attending meetings and/or travel	None	None	
8	Patents planned, issued or pending	None	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	None	
11	Stock or stock options	None	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	None	
13	Other financial or non- financial interests	None	None	

Т	ere is no conflict of interest	

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Jun Shang
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal sten
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

5				
3	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	None	
6	Payment for expert testimony	None	None	
7	Support for attending meetings and/or travel	None	None	
8	Patents planned, issued or pending	None	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	None	
11	Stock or stock options	None	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	None	
13	Other financial or non- financial interests	None	None	

Т	ere is no conflict of interest	

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Haoshuai Tang
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal ster
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

5				
3	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	None	
6	Payment for expert testimony	None	None	
7	Support for attending meetings and/or travel	None	None	
8	Patents planned, issued or pending	None	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	None	
11	Stock or stock options	None	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	None	
13	Other financial or non- financial interests	None	None	

Т	ere is no conflict of interest	

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Junjin Li
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal sten
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events None					
testimony Support for attending meetings and/or travel Begin Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services None None	5	lectures, presentations, speakers bureaus, manuscript writing or	None	None	
B Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	6		None	None	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None None None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None None None None None None None	7		None	None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None 12 Receipt of equipment, Mone None None None None None None None N	8	I	None	None	
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	9	Safety Monitoring Board or	None	None	
11 Stock or stock options None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None	10	in other board, society, committee or advocacy	None	None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	11		None	None	
	12	materials, drugs, medical writing, gifts or other	None	None	
	13		None	None	

There is no conflict of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022	
Your Name:Min Wang	
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal ste	m
cells after cocultures with Schwann cells in vitro	
Manuscript number (if known): ATM-22-3073	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events None					
testimony Support for attending meetings and/or travel Begin Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services None None	5	lectures, presentations, speakers bureaus, manuscript writing or	None	None	
B Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	6		None	None	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None None None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None None None None None None None	7		None	None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None 12 Receipt of equipment, Mone None None None None None None None N	8	I	None	None	
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	9	Safety Monitoring Board or	None	None	
11 Stock or stock options None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None	10	in other board, society, committee or advocacy	None	None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	11		None	None	
	12	materials, drugs, medical writing, gifts or other	None	None	
	13		None	None	

There is no conflict of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Xiaohong Kong
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal ster
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events None					
testimony Support for attending meetings and/or travel Begin Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services None None	5	lectures, presentations, speakers bureaus, manuscript writing or	None	None	
B Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None	6		None	None	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None None None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None None None None None None None	7		None	None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None 12 Receipt of equipment, Mone None None None None None None None N	8	I	None	None	
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	9	Safety Monitoring Board or	None	None	
11 Stock or stock options None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None	10	in other board, society, committee or advocacy	None	None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	11		None	None	
	12	materials, drugs, medical writing, gifts or other	None	None	
	13		None	None	

There is no conflict of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Zhijian Wei
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal ster
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

None None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services None	5	lectures, presentations, speakers bureaus, manuscript writing or	None	None
Meetings and/or travel	6		None	None
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None None None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None None None None None None None	7		None	None
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None 12 Receipt of equipment, Mone None None None None None None None N	8	I	None	None
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	9	Safety Monitoring Board or	None	None
11 Stock or stock options None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None	10	in other board, society, committee or advocacy	None	None
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	11		None	None
	12	materials, drugs, medical writing, gifts or other	None	None
	13		None	None

There is no conflict of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:12 th June 2022
Your Name:Shiqing Feng
Manuscript Title: Quantitative iTRAQ proteomics reveal the proteome profiles of bone marrow mesenchymal ster
cells after cocultures with Schwann cells in vitro
Manuscript number (if known): ATM-22-3073

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

None None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services None	5	lectures, presentations, speakers bureaus, manuscript writing or	None	None
Meetings and/or travel	6		None	None
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None None None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None None None None None None None	7		None	None
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None 12 Receipt of equipment, Mone None None None None None None None N	8	I	None	None
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None None None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	9	Safety Monitoring Board or	None	None
11 Stock or stock options None None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None	10	in other board, society, committee or advocacy	None	None
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	11		None	None
	12	materials, drugs, medical writing, gifts or other	None	None
	13		None	None

There is no conflict of interest		

Please place an "X" next to the following statement to indicate your agreement: